NAV

Perflubron

Identification

Generic Name
Perflubron
DrugBank Accession Number
DB05791
Background

Perflubron (Oxygent) is being developed as an intravascular oxygen carrier designed to augment oxygen delivery in surgical patients.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 498.962
Monoisotopic: 497.891192132
Chemical Formula
C8BrF17
Synonyms
  • Perflubron
  • Perfluorooctyl-bromide
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Investigated for use/treatment in cardiac surgery, hemorrhage, and ileus.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Perflubron emulsion (Oxygent) maintains hemodynamic stability during major surgery, thereby potentially reducing or avoiding intraoperative transfusions of donor blood in major surgery.Perflubron emulsion has ability to enable patients to be physiologically stable and safe at lower intraoperative Hb levels.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Oxygent

Categories

ATC Codes
V08CX01 — Perflubron
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.
Kingdom
Organic compounds
Super Class
Organohalogen compounds
Class
Organofluorides
Sub Class
Not Available
Direct Parent
Organofluorides
Alternative Parents
Organobromides / Hydrocarbon derivatives / Alkyl fluorides / Alkyl bromides
Substituents
Aliphatic acyclic compound / Alkyl bromide / Alkyl fluoride / Alkyl halide / Hydrocarbon derivative / Organobromide / Organofluoride
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
fluoroalkane (CHEBI:38803)
Affected organisms
Not Available

Chemical Identifiers

UNII
Q1D0Q7R4D9
CAS number
423-55-2
InChI Key
WTWWXOGTJWMJHI-UHFFFAOYSA-N
InChI
InChI=1S/C8BrF17/c9-7(22,23)5(18,19)3(14,15)1(10,11)2(12,13)4(16,17)6(20,21)8(24,25)26
IUPAC Name
1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-heptadecafluorooctane
SMILES
FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br

References

General References
  1. Gale SC, Gorman GD, Copeland JG, McDonagh PF: Perflubron emulsion prevents PMN activation and improves myocardial functional recovery after cold ischemia and reperfusion. J Surg Res. 2007 Mar;138(1):135-40. Epub 2006 Dec 14. [Article]
  2. Rosen NA, Hopf HW, Hunt TK: Perflubron emulsion increases subcutaneous tissue oxygen tension in rats. Wound Repair Regen. 2006 Jan-Feb;14(1):55-60. [Article]
PubChem Compound
9873
PubChem Substance
175427032
ChemSpider
9489
ChEBI
38803
ChEMBL
CHEMBL1200866
ZINC
ZINC000008214650
Wikipedia
Oxygent

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAsthma1
1CompletedTreatmentChronic Lung Disease of Prematurity1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0314 mg/mLALOGPS
logP4.74ALOGPS
logP6.64Chemaxon
logS-4.2ALOGPS
Physiological Charge0Chemaxon
Hydrogen Acceptor Count0Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area0 Å2Chemaxon
Rotatable Bond Count7Chemaxon
Refractivity48.52 m3·mol-1Chemaxon
Polarizability21.18 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9896
Caco-2 permeable+0.6277
P-glycoprotein substrateNon-substrate0.8924
P-glycoprotein inhibitor INon-inhibitor0.9533
P-glycoprotein inhibitor IINon-inhibitor0.9264
Renal organic cation transporterNon-inhibitor0.9207
CYP450 2C9 substrateNon-substrate0.8648
CYP450 2D6 substrateSubstrate0.7099
CYP450 3A4 substrateNon-substrate0.7486
CYP450 1A2 substrateNon-inhibitor0.6432
CYP450 2C9 inhibitorNon-inhibitor0.7876
CYP450 2D6 inhibitorNon-inhibitor0.9515
CYP450 2C19 inhibitorNon-inhibitor0.7867
CYP450 3A4 inhibitorNon-inhibitor0.9553
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8993
Ames testNon AMES toxic0.8692
CarcinogenicityCarcinogens 0.6509
BiodegradationNot ready biodegradable0.9682
Rat acute toxicity1.6745 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9796
hERG inhibition (predictor II)Non-inhibitor0.9093
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0000900000-0e3c29a3fe364f36cd88
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0002-0000900000-d7310befcd149a506375
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-004j-0002900000-ec59d1eda5423d7a6524
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-174.38576
predicted
DeepCCS 1.0 (2019)
[M+H]+176.78133
predicted
DeepCCS 1.0 (2019)
[M+Na]+183.29051
predicted
DeepCCS 1.0 (2019)

Drug created at November 18, 2007 18:27 / Updated at February 21, 2024 02:33